Completed OBSERVATIONAL NCT03744806

Blood-aqueous Barrier Integrity in Eyes Undergoing Intravitreal Bevacizumab Therapy to Treat Neovascular AMD

Blood-aqueous Barrier Integrity in Eyes Undergoing Intravitreal Bevacizumab Therapy to Treat Neovascular Age-related Macular Degeneration

Sponsor: Medical University of Lublin

Conditions Exudative Age-related Macular Degeneration

Interventions Bevacizumab Injection

Updated 4 times since 2018 Last updated: Nov 15, 2018 Started: Jan 31, 2015 Primary completion: Sep 30, 2015 Completion: Aug 31, 2018

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03744806, this observational or N/A phase trial focuses on Exudative Age-related Macular Degeneration and remains completed. Sponsored by Medical University of Lublin, it has been updated 4 times since 2015, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

4 versions recorded

Sep 2024 — Present [monthly]

Completed
Jul 2024 — Sep 2024 [monthly]

Completed
Jan 2021 — Jul 2024 [monthly]

Completed
Dec 2018 — Jan 2021 [monthly]

Completed

First recorded

Jan 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Medical University of Lublin

Data source: Medical University of Lublin

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.